Shots:BMS & Bain Capital have launched a new independent biopharma company focused on autoimmune diseases, which will be backed by $300M funding commitment led by Bain & 5 immunology assets in-licensed from BMSAs per the deal, BMS will retain ~20% equity stake in the new company & is entitled to receive royalties & milestone payments for…
